Cat. No. Name Size Price Add Cart
KI1058PKI5875 mg$272
PKI58710 mg$472
PKI58750 mg$1170
PKI587200 mg$3700

Chemical Characteristic

Product NamePKI587
SynonymsPF-05212384
CAS No.1197160-78-3
Molecular Weight 615.32
FormulaC32H41N9O4
Chemical NameN-[4-[[4-(Dimethylamino)-1-piperidinyl]carbonyl]phenyl]-N'-[4-[4,6-di(4-morpholinyl)-1,3,5-triazin-2-yl]phenyl]urea
SmilesN(C(=O)Nc1ccc(cc1)c1nc(nc(n1)N1CCOCC1)N1CCOCC1)c1ccc(cc1)C(=O)N1CCC(CC1)N(C)C
Chemical Structure

Biological activities

PKI587 is a highly potent dual PI3K/mTOR kinase inhibitor. The IC50 of PKI587 is 0.4 nM against wild type PI3K-?. PKI587 inhibits mutant type PI3K-αE545K and PI3K-αH1047R with IC50 of 0.6 and 0.8 nM, respectively. In addition, PKI587 also blocks PI3K-β, PI3K-γ and PI3K-δ with IC50 of 6, 6 and 8 nM, respectively. In contrast, the IC50 of PKI587 is 1 nM against mTOR. PKI587 prevents growth of 50 diverse human tumor cell lines at IC50 values of less than 100 nM. PKI587 inhibits the growth of tumor cells MDA-MB-361, MDA-MB-468 and T47D with IC50 of 1, 6 and 2 nM, respectively. PKI587 suppresses the phosphorylation of PI3K/mTOR effectors (including Akt). PKI587 induces apoptosis in human tumor cell lines with elevated PI3K/mTOR signaling. PKI-587 at 25 mg/kg (single dose) suppresses p-Akt (T308 and S473) for up to 36 hours, with cPARP still evident at 18 hours. PKI587 inhibits EGF-stimulated AKT (ser473) activation.[2] PKI587 suppresses Akt phosphorylation at S473.[3] PKI587 prevents the proliferation of tumor in several models, including breast (MDA-MB-361, BT474), colon (HCT116), lung (H1975), and glioma (U87MG) xenograft models.[1] PKI587 reveals excellent antitumor efficacy in both subcutaneous and orthotopic xenograft tumor models when administered intravenously.[3]

Protocols

In vivo PKI587 is dissolved in 5% dextrose, water, pH 3.5.[1]

References

[1] Mallon R, et al. Antitumor efficacy of PKI-587, a highly potent dual PI3K/mTOR kinase inhibitor. Clin Cancer Res. 2011, 17(10): 3193-3203.
[2] Gedaly R, et al. PKI-587 and sorafenib targeting PI3K/AKT/mTOR and Ras/Raf/MAPK pathways synergistically inhibit HCC cell proliferation. J Surg Res. 2012, 176(2): 542-548.
[3] Venkatesan AM, et al. Bis(morpholino-1,3,5-triazine) derivatives: potent adenosine 5'-triphosphate competitive phosphatidylinositol-3-kinase/mammalian target of rapamycin inhibitors: discovery of compound 26 (PKI-587), a highly efficacious dual inhibitor. J Med Chem. 2010, 53(6): 2636-2645.

Please click here to fill online order form, and we will make sure to supply you product with detail information. This process usually takes between 24 to 48 hours, depending on products stock avaliability. All inquires and subsequent projects are handled in the strictest confidence and will be backed by a confidentiality agreement if required.
KareBayTM provides scientists and clinicians with a wide range of biotechnological products and science lab supplies for chemical research and analyzing life processes. KareBay's extensive capabilities include commercializing reagents and kits, manufacturing biotech products and providing contract research services to organizations worldwide. Our many global labs, offices, and business partners enable KareBay to extend its products and services to its customer base around the world.

Our products are used for research, laboratory and further evaluation purposes. They are not for human use.